Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Rhea-AI Summary
Celularity (Nasdaq: CELU) appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. He will lead global commercialization of cenplacel-L, the Lifebank cellular banking platform and the broader regenerative medicine portfolio, reporting to CEO Robert J. Hariri.
Gonzalez brings 20+ years of biotech and medtech leadership, including roles at Alume Biosciences, Navidea Biopharmaceuticals and Spectrum Pharmaceuticals, where he previously helped drive significant revenue expansion. Celularity cites growing physician demand in permissive markets for cenplacel-L and ongoing 2025 Lifebank sales as drivers to strengthen commercial capabilities.
AI-generated analysis. Not financial advice.
Positive
- Experienced CCO appointed to lead global commercialization of cenplacel-L and Lifebank
- Gonzalez previously oversaw 2.5x year-over-year revenue growth at Navidea
- Helped scale Spectrum Pharmaceuticals revenue from $7.7 million to about $300 million
- Company reports early commercial traction for cenplacel-L in permissive markets
- Lifebank generated sales in 2025, supporting longevity strategy execution
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CELU was down 0.93% pre-news, while peers like ABVC (-10.07%) and ARTV (-7.54%) also declined. Despite multiple peers moving lower, the momentum scanner did not flag a coordinated sector move, pointing to more stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 29 | Late 10-Q notice | Negative | +5.9% | Nasdaq notice for late Form 10-Q but no immediate listing impact. |
| May 01 | 10-K filing, compliance | Positive | +2.8% | Filed 2025 Form 10-K, regained Nasdaq compliance and cut liabilities. |
| Apr 21 | Asset sale to NexGel | Positive | -1.6% | Closed biomaterials asset sale, raised cash and reduced debt. |
| Apr 17 | Late 10-K notice | Negative | +0.8% | Nasdaq notice for late 10-K, with time to submit compliance plan. |
| Mar 12 | NEXGEL partnership | Positive | -0.8% | Reiterated biomaterials commercialization partnership and 510(k) programs. |
CELU’s price often diverged from the apparent tone of news, with several negative compliance headlines followed by modest gains and strategic positives sometimes met with weakness.
Over the last few months, Celularity navigated multiple Nasdaq compliance issues and strategic repositioning. It sold biomaterials assets for $13.3M, including $8.3M cash and a $5.0M convertible note, retiring nearly $13.0M of debt. A subsequent $13M liability reduction and filing of the 2025 Form 10-K restored listing compliance. Today’s CCO appointment fits the shift toward focused commercialization of longevity and cell therapy assets after monetizing non-core biomaterials.
Market Pulse Summary
This announcement underscores Celularity’s pivot from resolving compliance and balance-sheet issues toward commercial execution. After raising $13.3M from asset sales and cutting liabilities by $13M, the company highlighted cenplacel-L and Lifebank as core longevity and regenerative medicine assets. The CCO appointment ties directly to building global commercial infrastructure. Investors may watch future disclosures on revenue traction, regulatory progress for cenplacel-L, and continued operational discipline.
Key Terms
allogeneic medical
stem-cell medical
regenerative medicine medical
convertible promissory note financial
restricted stock units (RSUs) financial
510(k) pathway regulatory
Form 10-K regulatory
Nasdaq Listing Rule 5250(c)(1) regulatory
AI-generated analysis. Not financial advice.
Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company’s broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman, Chief Executive Officer and Founder.
“Rick’s appointment comes at an important time for Celularity as we continue to advance our revenue-generating strategy and expand the reach of our regenerative medicine platform,” said Robert J. Hariri. “Celularity was founded on the belief that the placenta represents a powerful biological resource with the potential to transform medicine at global scale. As physician and patient interest in cellular medicine continues to grow, we believe Rick’s experience building commercial organizations and executing disciplined growth strategies across complex healthcare markets will be important as we seek to expand responsible access to cenplacel-L, enhance our Lifebank offering, and translate Celularity’s science into long-term value for physicians, patients, families and shareholders.”
Mr. Gonzalez brings more than two decades of executive leadership experience across biotechnology, medical technology, precision medicine and digital health. Most recently, he served as Chief Commercial Officer of Alume Biosciences, where he led global commercialization strategy for a clinical-stage surgical visualization platform, including pricing, reimbursement, market access and launch readiness. He previously served as President, Chief Executive Officer and Director of Navidea Biopharmaceuticals, where he led commercialization of a precision diagnostic platform and drove 2.5x year-over-year revenue growth, and as Senior Vice President, Global Operations at Spectrum Pharmaceuticals, where he helped scale global revenue from
Cenplacel-L, clinically investigated as PDA-001 and PDA-002, is Celularity’s most mature placental-derived allogeneic cell therapy asset. The program reflects more than two decades of research by Celularity into the unique biological properties of postpartum placental cells. Celularity believes cenplacel-L has the potential to play an important role in the emerging global market for stem-cell and regenerative cellular therapies, particularly in jurisdictions where regulatory frameworks permit physician-directed access to such therapies.
The Company is seeing demand from physicians seeking access to high-quality, responsibly manufactured stem-cell therapies for appropriate patients in permissive markets. Since making cenplacel-L available to qualified physicians for investigational use in such jurisdictions, Celularity believes this early commercial traction supports the Company’s decision to strengthen its commercial leadership with the appointment of Mr. Gonzalez and the continued build-out of commercial capabilities designed to support appropriate physician engagement, education and market development.
Mr. Gonzalez will also lead expansion of Celularity’s Lifebank product offering for expectant parents and adults who wish to bank their own cells for potential future use. Lifebank generated sales in 2025 that reflected continued interest in cellular banking and its role in Celularity’s broader longevity and regenerative medicine strategy. Celularity believes Lifebank is a natural extension of that strategy, providing individuals and families with an opportunity to preserve valuable cellular material at a time when interest in proactive health, cellular medicine and future therapeutic optionality continues to grow. Under Mr. Gonzalez’s leadership, Celularity intends to strengthen commercial education around Lifebank, expand engagement with physicians and other healthcare providers, and broaden awareness among consumers seeking to preserve biological resources that may support future advances in regenerative medicine and human performance.
“I am honored to join Celularity at such a pivotal point in the Company’s evolution,” said Mr. Gonzalez. “Celularity has a differentiated foundation in placental-derived cellular therapy, a near-term commercial opportunity with cenplacel-L, the Lifebank cellular banking platform, and a broader mission that aligns with the growing demand for longevity and regenerative medicine. My focus will be on building disciplined commercial infrastructure, strengthening physician engagement, aligning cross-functional execution, and helping translate Celularity’s scientific and manufacturing capabilities into sustainable commercial growth. I look forward to working with the team to expand access responsibly, support physicians and patients, and create long-term value for the Company and its stakeholders.”
Celularity believes the next phase of regenerative medicine will be defined not only by demand for innovative cellular therapies, but also by manufacturing rigor, quality systems, regulatory discipline and clinically responsible access. The Company’s current manufacturing infrastructure and existing inventory position it to support anticipated demand for cenplacel-L while maintaining the quality standards and manufacturing discipline central to Celularity’s platform.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.
For more information, please visit www.celularity.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including statements regarding Celularity’s commercial strategy, leadership appointments, longevity strategy, product opportunities, physician demand, responsible access, market expansion, Lifebank, cellular banking, future therapeutic optionality, revenue generation, growth prospects, manufacturing capabilities, anticipated demand, participating centers, repeat physician utilization, patient cohorts, and anticipated value creation. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks described in Celularity’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Celularity undertakes no obligation to update any forward-looking statements, except as required by law.
Carlos Ramirez
SVP, Investor Relations
Celularity Inc.
Carlos.ramirez@celularity.com
